Biofrontera (BFRI) to Release Earnings on Monday

Biofrontera (NASDAQ:BFRIGet Rating) will post its quarterly earnings results before the market opens on Monday, November 14th. Analysts expect Biofrontera to post earnings of ($0.32) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Biofrontera (NASDAQ:BFRIGet Rating) last released its quarterly earnings data on Friday, August 12th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.13). The company had revenue of $4.46 million during the quarter, compared to analyst estimates of $4.58 million. Biofrontera had a negative net margin of 93.13% and a negative return on equity of 482.89%. On average, analysts expect Biofrontera to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biofrontera Trading Up 5.3 %

NASDAQ BFRI opened at $1.00 on Friday. The company has a market cap of $26.70 million and a PE ratio of -0.33. Biofrontera has a 12 month low of $0.82 and a 12 month high of $14.63. The stock has a 50 day moving average of $1.09 and a 200-day moving average of $1.76.

Institutional Investors Weigh In On Biofrontera

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of Biofrontera in the 1st quarter valued at approximately $48,000. State Street Corp acquired a new stake in shares of Biofrontera in the 1st quarter valued at approximately $49,000. Northern Trust Corp acquired a new stake in shares of Biofrontera in the 2nd quarter valued at approximately $39,000. Finally, BlackRock Inc. boosted its holdings in shares of Biofrontera by 894.0% in the 1st quarter. BlackRock Inc. now owns 100,505 shares of the company’s stock valued at $335,000 after buying an additional 90,394 shares during the last quarter. Institutional investors and hedge funds own 6.84% of the company’s stock.

About Biofrontera

(Get Rating)

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

Featured Articles

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with's FREE daily email newsletter.